BridgeBio Pharma develops medicines for genetic diseases and cancers driven by genetic alterations. The company runs a multi-program model that advances several drug candidates in parallel across rare Mendelian disorders and genetically defined oncology. Its pipeline spans small molecules and other modalities aimed at well-characterized molecular targets. The focus is precision medicine for patients with high unmet medical need rather than broad primary-care markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 110.6 | — | -181.9 | — |
| Q3 2025 | 120.7 | — | -182.7 | — |
| Q4 2025 | 154.2 | — | -192.9 | — |
| Q1 2026 | 194.5 | — | -164 | — |
| Q2 2026 | 243.7 | 120.4% | -152.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: The Carlyle Group Inc. (CG), Manhattan Associates, Inc. (MANH), Semtech Corporation (SMTC), Erie Indemnity Company (ERIE), Akamai Technologies, Inc. (AKAM), SEI Investments Company (SEIC)